Crossmark

Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry

Crossref DOI link: https://doi.org/10.1038/s41598-022-25399-5

Published Online: 2022-12-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morin-Dewaele, Margot

Bartier, Sophie

Berry, François

Brillet, Rozenn

López-Molina, Dennis Salomón

Nguyễn, Công Trung

Maille, Pascale

Sereno, Kevin

Nevers, Quentin

Softic, Laurent

Vaugeois, Jean-Marie

Louis, Bruno

Bequignon, Emilie

Bruscella, Patrice http://orcid.org/0000-0002-0719-0826
Coste, André

Pawlotsky, Jean-Michel http://orcid.org/0000-0003-0745-7559
Jamain, Stéphane

Ahmed-Belkacem, Abdelhakim http://orcid.org/0000-0001-6489-5091
Funding

Funding for this research was provided by:

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Fondation pour la Recherche Médicale (ANR Flash COVID)

Agence Nationale de la Recherche (ANR Flash COVID)
License Information

Text and Data Mining valid from 2022-12-06

Version of Record valid from 2022-12-06
More Information

Article History

Received: 12 January 2022

Accepted: 28 November 2022

First Online: 6 December 2022

Competing interests

: J-M.P. has served as an advisor and/or speaker for Abbvie, Gilead, Merck, Regulus, Assembly Biosciences, Arbutus and Memo Therapeutics. A.C. has participated in advisory boards for ALK, GSK and Sanofi. The rest of the authors have no competing interest.

Document is current

Any future updates will be listed below